Gandhi S, Shastri D, Shah J, Nair A, Jacob S
Pharmaceutics. 2024; 16(4).
PMID: 38675142
PMC: 11055100.
DOI: 10.3390/pharmaceutics16040481.
Dekeyser A, Huart C, Hummel T, Hox V
Int J Mol Sci. 2024; 25(8).
PMID: 38674045
PMC: 11050448.
DOI: 10.3390/ijms25084460.
Fang S, Rui X, Zhang Y, Yang Z, Wang W
PeerJ. 2024; 12:e17227.
PMID: 38618567
PMC: 11015827.
DOI: 10.7717/peerj.17227.
Calvo-Henriquez C, Garcia-LLiberos A, Sanchez-Gomez S, Alobid I
Eur Arch Otorhinolaryngol. 2024; 281(8):3915-3928.
PMID: 38459984
DOI: 10.1007/s00405-024-08531-1.
Espehana A, Lee L, Garden E, Klyvyte G, Gokani S, Jegatheeswaran L
J Clin Med. 2023; 12(23).
PMID: 38068438
PMC: 10707438.
DOI: 10.3390/jcm12237387.
Instantaneous Formation of Silk Protein Aerosols and Fibers with a Portable Spray Device Under Ambient Conditions.
Choi J, Sahoo J, Hasturk O, Falcucci T, Yao Y, Kaplan D
Adv Mater Technol. 2023; 8(7).
PMID: 37635855
PMC: 10456984.
DOI: 10.1002/admt.202201392.
Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.
Sibinovska N, Zakelj S, Trontelj J, Kristan K
Pharmaceutics. 2022; 14(2).
PMID: 35214101
PMC: 8877043.
DOI: 10.3390/pharmaceutics14020369.
First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines.
Charalambous M, Volk H, Van Ham L, Bhatti S
BMC Vet Res. 2021; 17(1):103.
PMID: 33663513
PMC: 7934266.
DOI: 10.1186/s12917-021-02805-0.
Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs.
Kim J, Kim M, Baek I
Pharmaceutics. 2018; 10(4).
PMID: 30326564
PMC: 6321473.
DOI: 10.3390/pharmaceutics10040187.
Intranasal Midazolam versus Rectal Diazepam for the Management of Canine Status Epilepticus: A Multicenter Randomized Parallel-Group Clinical Trial.
Charalambous M, Bhatti S, Van Ham L, Platt S, Jeffery N, Tipold A
J Vet Intern Med. 2017; 31(4):1149-1158.
PMID: 28543780
PMC: 5508334.
DOI: 10.1111/jvim.14734.
Effect of Variable Inspiratory Flow Rate on the Performance of the Budesonide Rhinocort Turbuhaler™.
Devalia J, Prime D, Richards D
Clin Drug Investig. 2016; 21(3):195-201.
PMID: 27517549
DOI: 10.2165/00044011-200121030-00005.
Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model.
Rygg A, Longest P
J Aerosol Med Pulm Drug Deliv. 2016; 29(5):416-431.
PMID: 26824178
PMC: 8662553.
DOI: 10.1089/jamp.2015.1252.
Current understanding of nasal morphology and physiology as a drug delivery target.
Suman J
Drug Deliv Transl Res. 2015; 3(1):4-15.
PMID: 25787863
DOI: 10.1007/s13346-012-0121-z.
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?.
Van Woensel M, Wauthoz N, Rosiere R, Amighi K, Mathieu V, Lefranc F
Cancers (Basel). 2013; 5(3):1020-48.
PMID: 24202332
PMC: 3795377.
DOI: 10.3390/cancers5031020.
Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial.
Gyanesh P, Haldar R, Srivastava D, Agrawal P, Tiwari A, Singh P
J Anesth. 2013; 28(1):12-8.
PMID: 23800984
DOI: 10.1007/s00540-013-1657-x.
Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.
Djupesland P
Drug Deliv Transl Res. 2013; 3(1):42-62.
PMID: 23316447
PMC: 3539067.
DOI: 10.1007/s13346-012-0108-9.
Septoplasty and decongestant improve distribution of nasal spray.
Mi J, Fan Y, Feng S, Xia W, Wang J, Li H
J Huazhong Univ Sci Technolog Med Sci. 2011; 31(6):837-841.
PMID: 22173509
DOI: 10.1007/s11596-011-0687-6.
Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches.
Kariyawasam H, Scadding G
Allergy Asthma Immunol Res. 2011; 3(4):226-35.
PMID: 21966602
PMC: 3178820.
DOI: 10.4168/aair.2011.3.4.226.
Topical antibiotic therapy of chronic rhinosinusitis.
Comstock 3rd R, Lam K, Mikula S
Curr Infect Dis Rep. 2011; 12(2):88-95.
PMID: 21308504
DOI: 10.1007/s11908-010-0085-4.
Influence of anatomy and head position on intranasal drug deposition.
Merkus P, Ebbens F, Muller B, Fokkens W
Eur Arch Otorhinolaryngol. 2006; 263(9):827-32.
PMID: 16807754
DOI: 10.1007/s00405-006-0071-5.